

**2022**

	688238.SH

{2022}61

10,000.00

1.00

13.23

1,323,000,000.00

1,197,464,432.14

2022 3 22

2022 3 22 2025 12 31

2022 3 22 2022 12 31

" "

11 —

**2022**

1	
2	

3	
4	
5	2023 4 19 2023 4 26

	"
	"

16	
18	
15	

--	--

& &













	249,007.79	126,343.79	97.09
	<b>2022</b>	<b>2021</b>	<b>%</b>
	0.083	0.138	-39.86
	0.083	0.138	-39.86
	0.066	0.104	-36.54
%	2.12	6.16	4.04
%	1.67	4.65	2.98
%	11.96	9.26	2.7

"

"

"

"

			%
	3,482.75	2,361.60	47.47
	-	-	-
	3,482.75	2,361.60	47.47
%	11.96	9.26	2.7
%	-	-	-

	6	10	61	22
	1	1	5	4
	2	0	2	0
	0	0	1	1
	26	12	117	59
	35	23	186	86

		A	119,746.44
		B1	
		B2	
		C1	52,106.25
		C2	1,674.24
		D1=B1+C1	52,106.25
		D2=B2+C2	1,674.24
		E=A-D1+D2	69,314.43
		F	58,764.43
		G=E-F	10,550.00

10,550.00

1 2022 12 31

	98860078801600001960	40,710.34	
	98860078801100001959	10,121.91	
	121929394110858	244.67	
	121938180510616	3,665.78	
	50131000890396571	1,036.53	
	2900001010120100061913	2,985.20	



	<b>58,764.43</b>	
--	------------------	--

20      12      31

		2022   7   29	2025   7   29	10,000.00
		2022   7   6	2023   7   6	550.00
				<b>10,550.00</b>

---

---



(本页无正文, 为《海通证券股份有限公司关于和元生物技术(上海)股份有限公司 2022 年度持续督导年度跟踪报告》之签字盖章页)

保荐代表人签名:

181289

陈恒瑞

270026

张子慧

